Hi, I am David A. Johnson, My LiveDNA is 1.5982
 
   
  Home
 
 
 
Dr. David A. Johnson
 
Highest Degree: M.D. in Psychology from University of Virginia, Charlottesville, Virginia, USA
 
Institute: Eastern Virginia Medical School, USA
 
Area of Interest: Biomedical Sciences
  •   Ear Nose Throat
  •   Gastroenterology
  •   Radiology
  •   Pharmacotherapy
 
URL: http://livedna.org/1.5982
 
My SELECTED Publications
1:    Johnson, D.A., 1989. Diarrhea in critically ill patients. Am. Fam. Physician, 3: 392-410.
PubMed  |  
2:   Bhatt, D., J. Schieman, N. Abraham and D.A. Johnson, 2008. Multisociety position consensus on antiplatelet/NSAID therapy in cardiology patients with GI risk. Am. J. Gastroenterol., 103: 2890-2907.
3:   Cattau, E.L. Jr. and D.A. Johnson, 1987. Postcholecystectomy Syndrome. In: A Manual of Clinical Problems in Gastroenterology, Chobanian S.J. and M.M. van Ness (Eds.). Little, Brown and Company, Boston, pp: 220-222.
4:   Cattau, E.L. Jr., D.O. Castell, D.A. Johnson, T.J. Spurling, R. Hirszel, S.J. Chobanian and J.E. Richter, 1991. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am. J. Gastroenterol., 86: 272-276.
PubMed  |  
5:   Chand, N., D.A. Johnson, M. Tabangin and J.C. Ware, 2004. Sleep dysfunction in patients with gastro-oesophageal reflux disease: Prevalence and response to GERD therapy, a pilot study. Aliment Pharm., 20: 969-974.
PubMed  |  
6:   Chobanian, S.J., E.L. Cattau, D.A. Johnson, C. Winters and M.M. van Ness, 1987. In vivo staining with toluidine blue as an adjunct to the endoscopic detection of Barrett's esophagus. Gastro Endosc, 33: 99-101.
PubMed  |  
7:   Chobian, S.J., C. Winters Jr., D.A. Johnson, W. Martland, J.L. Buck and E.L. Cattau Jr., 1986. Esophageal pseudoworm: Pasta not parasite. Ann. Intern. Med., 105: 138-138.
PubMed  |  Direct Link  |  
8:   Cohen, L., D. Johnson, R. Ganz, J. Aisenberg and J. Deviere et al., 2005. Enteryx implantation for GERD: Expanded multicenter trial results and interim post-approval follow-up to 24 months. Gastrointest Endosc, 61: 650-659.
PubMed  |  
9:   Collen, M.J and D.A. Johnson, 1992. Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus. Dig. Dis. Sci., 37: 570-576.
PubMed  |  
10:   Collen, M.J., D.A. Johnson and M.J. Sheridan, 1994. Basal acid output and gastric hypersecretion in gastroesophageal reflux disease: correlation with ranitidine therapy. Diges. Dis. Sci., 39: 410-417.
11:   Devault, K., J. Johanssen and D.A. Johnson, 2006. Esomeprazole versus lansoprazole for maintenance therapy for GERD-a prospective controlled trial. Clin. Gastro Hepatol., 4: 852-859.
12:   Drane, W.E. and D.A. Johnson, 1990. Sincalide-augmented quantitative hepato-biliary scintigraphy definition of normal parameters and evaluation of biliary dyskinesia. J. Nucl. Med., 31: 1462-1468.
13:   Drane, W.E., D.A. Johnson and E.L. Cattau, 1987. Scintigraphic assessment of nutcracker esophagus: A reevaluation. Radiology, 163: 33-38.
14:   Drane, W.E., D.A. Johnson, K.C. Karvelis, J. Curran and E.D. Silverman, 1987. Metoclopramide effects on esophageal function. J. Nucl. Med., 28: 810-815.
15:   Drane, W.E., G.A. Krasicky and D.A. Johnson, 1987. Radionuclide imaging of primary tumors and tumor-like conditions of the liver. Clin. Nucl. Med., 12: 569-582.
PubMed  |  
16:   Drane, W.E., K. Karvelis, D.A. Johnson, J.J. Curran and E.D. Silverman, 1986. Progressive systemic sclerosis: Radionuclide esophageal scintigraphy and manometry. Radiology, 160: 73-76.
PubMed  |  Direct Link  |  
17:   Drane, W.E., K.C. Karvelis, D.A. Johnson and E.D. Silverman, 1987. Scintigraphic evaluation of duodenogastric reflux. Problems, pitfalls, and technical review. Clin. Nucl. Med., 12: 377-384.
PubMed  |  
18:   Elsakr, R., D.A. Johnson, Z. Younes and E.C. Oldfield, 1998. Antimicrobial treatments of intraabdominal infection. Digestive Dis., 16: 47-60.
CrossRef  |  
19:   Fennerty, M.B. and D.A. Johnson, 2004. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology, 126: 660-664.
CrossRef  |  PubMed  |  
20:   Fennerty, M.B., D. Castell, A.M. Fendrick, M. Halpern and D. Johnson et al., 1996. The diagnosis and treatment of Gastroesophageal Reflux Disease in a managed care environment. Arch. Int. Med., 156: 477-484.
PubMed  |  
21:   Hacker, J.F., S.J. Chobanian, D.A. Johnson, C. Winters and E.L. Cattau, 1987. Patient acceptability of per gastrointestinal radiography versus endoscopy. South J. Med., 80: 1091-1093.
22:   Itzkowitz, S., R. Brand, L. Jandorf, K. Durkee and J. Millholland et al., 2008. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol., 103: 2862-2870.
CrossRef  |  
23:   Johnson, D.A. and A. Roach, 2003. Alternative dosing strategies for esomeprazole. Pharmacotherapy, 23: 731-734.
24:   Johnson, D.A. and B.H. Levy, 2010. Evolving drugs in gastroesophageal reflux disease: Pharmacologic treatment beyond proton pump inhibitors. Exp. Opin., 11: 1541-1548.
CrossRef  |  
25:   Johnson, D.A. and C. Everhart, 1986. Colitis in Bechet's syndrome. Gastrointest Endosc., 32: 9-60.
26:   Johnson, D.A. and D.K. Rex, 2000. Colon cancer screening: American college of gastroenterology screening registry. Am. J. Gastroenterol., 95: 868-877.
27:   Johnson, D.A. and E.L. Cattau Jr., 1986. Stool chemistries in evaluation of diarrheal disorders. Am. Fam. Physician., 33: 131-134.
28:   Johnson, D.A. and E.L. Cattau, 1992. Hepatopulmonary syndrome: Qualification of the defect. Am. J. Gastroenterol., 87: 401-402.
Direct Link  |  
29:   Johnson, D.A. and E.L. Cattau, Jr., 1987. Gastric Ulcer. In: A Manual of Clinical Problems in Gastroenterology, Chobanian S.J. and M.M. van Ness (Eds). Little, Brown and Company, Boston, MA, pp: 43.
CrossRef  |  
30:   Johnson, D.A. and K.F. Wagner, 1985. Antibiotic therapy based on stained peripheral blood smear. Arch. Intern. Med., 145: 369-370.
CrossRef  |  Direct Link  |  
31:   Johnson, D.A. and M. Bohan, 1983. Propoxyphene withdrawal with clonidine. Am. J. Psychiatry, 140: 1217-1218.
PubMed  |  Direct Link  |  
32:   Johnson, D.A. and M.B. Fennerty, 2004. Effect of Aging on symptom recognition and prevalence of erosive esophagitis. Gastroenterology, 126: 660-664.
33:   Johnson, D.A. and T. Parlette, 1983. Insulin-induced hyperlipodystrophy. Cutis, 32: 273-276.
34:   Johnson, D.A. and T.V. Whalen, 1983. Toxic tricyclic antidepressant levels and the EEG. JAMA, 250: 1027-1027.
35:   Johnson, D.A. and T.V. Whalen, 1985. Lactic acidosis and neoplastic diseases. Military Med., 150: 206-208.
36:   Johnson, D.A. and Z. Younes, 1999. Complications of endoscopy. J. Clin. Gastroenterol, 29: 306-317.
37:   Johnson, D.A. and Z. Younes, 1999. Symptoms in gastroesophageal reflux disease. Gastroenterol Clin NA, 28: 809-830.
38:   Johnson, D.A. and Z.Younes, 1997. Molecular and genetic advances in gastrointestinal cancer: State of the art. Digestive Dis., 15: 275-301.
PubMed  |  
39:   Johnson, D.A., 1987. Barrett's Esophagus. In: A manual of Clinical Problems in Gastroenterology, Chobanian, S.J. and M.M. van Ness (Eds)., Little, Brown and Company, Boston, MA., pp: 22-26.
40:   Johnson, D.A., 1987. Chronic Diarrhea. In: Manual of Clinical Problems in Gastroenterology, Chobanian S.J. and M.M. van Ness (Eds). Little, Brown and Company, Boston, MA, pp: 86-90.
41:   Johnson, D.A., 1987. Gastritis. In: Manual of Clinical Problems in Gastroenterology, Chobanian S.J. and M.M. van Ness (Eds). Little, Brown and Company, Boston, MA., pp: 40-43.
42:   Johnson, D.A., 1989. Antispasmodic Agents. In: Manual of Gastrointestinal Pharmacology, Van Ness, M.N. and M.S. Gurney (Eds.). Little, Brown and Company, Boston, MA., pp: 320-329.
43:   Johnson, D.A., 1989. Calcium Channel Blockers. In: Manual of Gastrointestinal Pharmacology, Van Ness, M.N. and M.S. Gurney (Eds.). Little, Brown and Company, Boston, MA., pp: 365-374.
44:   Johnson, D.A., 1990. The evaluation and management of extrahepatic obstructive jaundice. Forum, 5: 1-9.
45:   Johnson, D.A., 1991. Esophageal Involvement in other Inflammatory Diseases. In: Clinical Esophagology, Castell, D.O. (Ed.). Little, Brown and Company, Boston, MA., pp: 687-704.
46:   Johnson, D.A., 1991. Noncardiac chest pain. Forum, 6: 14-21.
47:   Johnson, D.A., 1991. Nonulcer Dyspepsia. In: Handbook of Experimental Pharmacology, Collen, M.J. and S.B. Benjamin (Eds.). Springer, Berlin, Heidelberg, New York, pp: 229-261.
48:   Johnson, D.A., 1991. Screening colonoscopy: Is it time for the wave? Am. J. Gastroenterol., 86: 784-785.
49:   Johnson, D.A., 1992. Diffuse Esophageal Spasm. In: Medicine for the Practicing Physician, Hurst, J.W. (Ed)., Butterworth Publishers, United Kingdom, pp:1473-1477.
50:   Johnson, D.A., 1992. Medical therapy of gastroesophageal reflux. Am. J. Med., 52: 88-92.
51:   Johnson, D.A., 1992. Noncardiac Chest Pain. In: Medicine for the Practicing Physician, Hurst, J.W. (Ed)., Butterworth Publishers, United Kingdom, pp: 1471-1473.
52:   Johnson, D.A., 1993. Barrettss Esophagus. In: Manual of Clinical Problems in Gastroenterology, Chobanian, S.J. and N.M. van Ness (Eds.). Little, Brown and Company, Boston, MA., pp: 28-32.
53:   Johnson, D.A., 1993. Chronic Diarrhea. In: Manual of Clinical Problems in Gastroenterology, Chobanian, S.J. and N.M. van Ness (Eds). Little, Brown and Company, Boston, MA., pp: 91-96.
54:   Johnson, D.A., 1993. Colon cancer screening issues. Forum, 8: 2-7.
55:   Johnson, D.A., 1994. Deciphering the cryptic nature of GERD-induced cough. Am. J. Gastroenterol., 89: 1594-1595.
PubMed  |  
56:   Johnson, D.A., 1994. Protean manifestations of intraabdominal lymphoma. Gastroenterol. Observer, 13: 2-8.
57:   Johnson, D.A., 1995. The gastric volvulus. Gastroenterol. Observer, 14: 2-8.
58:   Johnson, D.A., 1995. When and how to treat Helicobacter pylori infection. Family Practice Recertification, 17: 44-59.
59:   Johnson, D.A., 1996. Helicobacter pylori: Issues and answers. Consultant, 36: 1911-1923.
60:   Johnson, D.A., 1996. Medical therapy of GERD: Current state of the art. Hospital Practice, 31: 135-148.
PubMed  |  
61:   Johnson, D.A., 1996. New dimensions in Helicobacter pylori infection. Emergency Med., 28: 74-86.
62:   Johnson, D.A., 1997. Congenital esophageal stenosis. Gastroenterology Observer, 14: 2-4.
63:   Johnson, D.A., 1997. Gastroesophageal reflux disease: Long-term management strategies. Consultant, 37: 1833-1844.
64:   Johnson, D.A., 1997. Gastroesophageal reflux disease: Short-term management strategies. Consultant, 37: 1329-1348.
65:   Johnson, D.A., 1998. Fecal occult blood testing-problems, pitfalls and diagnostic concerns. Postgrad Med., 85: 287-299.
66:   Johnson, D.A., 1998. Intestinal spirochetosis. Gastroenterol. Observer, 17: 2-8.
67:   Johnson, D.A., 1999. Alteration in visceral perceptions represent primary pathophysiology in chest pain of unexplained etiology. Practical. Gastronterol., 23: 70-78.
68:   Johnson, D.A., 1999. Esophageal Involvement in other Inflammatory Conditions. In: The Esophagus, Castell, D.O. and J.E. Richter (Ed.). Williams and Wilkins, Philadelphia, pp: 565-580.
69:   Johnson, D.A., 2000. Consensus conference on gastroesophageal reflux disease. Consensus statement. J. Clin. Gastroenterol., 30: 51-53.
70:   Johnson, D.A., 2000. Visceral perception: Its role in functional bowel disorder/chest pain. Practical. Gastroenterol., 24: 72-74.
71:   Johnson, D.A., 2003. Alternative dosing for PPI therapy: Rationale and options. Rev. Gastroenterol. Disord., 3: S10-15.
PubMed  |  
72:   Johnson, D.A., 2003. Endoscopic therapy for GERD: An evidence based approach. Rev. Gastroenterol. Dis., 3: 142-149.
73:   Johnson, D.A., 2003. Endoscopic, deep mural implantation of Enteryx. Am. J. Gastroenterol., 98: 1893-1894.
74:   Johnson, D.A., 2003. Review of esomeprazole in the treatment of acid disorders. Exp. Opin. Pharmacother., 4: 253-264.
PubMed  |  
75:   Johnson, D.A., 2004. Acid inhibition-related therapy- gastroesophageal reflux disease and beyond: Hot topics and new insights. Rev. Gastroenterol. Disord., 4: S1-S2.
76:   Johnson, D.A., 2004. Endoscopic therapy for GERD: A systematic review. Minerva Gastroenterol, Dietol., 50: 239-251.
77:   Johnson, D.A., 2004. Endpoints for the assessment of response to gastroesophageal reflux disease therapy-what are the appropriate measures of ''success''? Rev. Gastroenterol Dis., 4: 118-128.
PubMed  |  
78:   Johnson, D.A., 2004. Evidence based assessment of the efficacy of esomeprazole for the healing of erosive esophagitis. Exp. Rev. Pharmacoeconomics Outcomes Res., 4: 371-382.
CrossRef  |  
79:   Johnson, D.A., 2004. Gastroesophageal reflux disease in the elderly-a prevalent and severe disease. Rev. Gastroenterol. Disord., 4: S16-24.
PubMed  |  
80:   Johnson, D.A., 2005. Endoluminal therapy for GERD-effective and here to stay. AGA Perspectives, 1: 4-9.
81:   Johnson, D.A., 2005. Endoscopic therapy for GERD: Becoming an attractive option? World Gastro, 10: 13-16.
82:   Johnson, D.A., 2005. Enteryx for gastroesophageal reflux disease. Expert Rev. Med. Devices, 2: 19-26.
83:   Johnson, D.A., 2005. Enteryx implant for gastroesophageal reflux disease. Curr. Treat Options Gastroenterol., 8: 51-57.
PubMed  |  
84:   Johnson, D.A., 2005. Medical Therapy for GERD: Defining Appropriate Outcomes and Management Strategies. In: Failed Antireflux Therapy: Evaluation and Management, Ferguson, M.K. and M.B. Fennerty (Eds.). Springer-Verlag, London, UK., pp: 31-45.
85:   Johnson, D.A., 2005. Obesity issues for gastroenterologists. Gastroenterol. Clin. N. Am., 34: 6-9.
86:   Johnson, D.A., 2006. Treating chronic constipation: How should we interpret the recommendations? Clin. Drug Invest., 26: 547-557.
PubMed  |  
87:   Johnson, D.A., 2008. Medical therapy for suspected GERD laryngitis. Clin. Gastro, 43: 589-594.
88:   Johnson, D.A., 2008. Medical therapy of reflux laryngitis. J. Clin. Gastroenterol., 42: 589-593.
CrossRef  |  
89:   Johnson, D.A., 2009. Questioning virtual colonoscopy. Radiol. Today, 10: 5-7.
90:   Johnson, D.A., A.M. Diehl, F. Finkelman and E.L. Cattau Jr., 1985. Crohn's disease and systemic lupus erythematosus. Am. J. Gastroenterol., 80: 869-870.
91:   Johnson, D.A., A.M. Diehl, M.H. Sjogren, J. Lazar, E.L. Jr. Cattau and R.C. Smallridge, 1987. Serum angiotensin converting enzyme activity in evaluation of patients with liver disease. Am. J. Med., 83: 256-260.
PubMed  |  
92:   Johnson, D.A., C. Perdomo and J.Barth, 2000. Rabeprazole: Safety profile of the new proton pump inhibitor. Eur. J. Gastroenterol. Hepatol., 12: 1-8.
93:   Johnson, D.A., C. Winters, T.J. Spurling, S.J. Chobanian and E.L. Cattau, 1986. Esophageal acid sensitivity in Barrett's esophagus. J. Clin. Gastro., 31: 1217-1220.
94:   Johnson, D.A., E.L. Cattau Jr. and C. Winters Jr., 1986. Biliary dyskinesia with associated high amplitude esophageal peristaltic contractions. Am. J. Gastroenterol., 81: 254-256.
PubMed  |  Direct Link  |  
95:   Johnson, D.A., E.L. Cattau Jr. and H.F. Zimmerman, 1986. Dapsone hepato-toxicity. Arch. Intern. Med., 146: 875-877.
96:   Johnson, D.A., E.L. Cattau Jr. and J. Hancock, 1985. Primary crohn's disease of the oropharynx. Ear Nose Throat, 64: 43-46.
97:   Johnson, D.A., E.L. Cattau, A. Khan, S.J. Chobanian and D. Newell, 1987. Fiberoptic endoscopy in a nasopharyngeal intubation. Gastrointest Endosc, 33: 32-33.
98:   Johnson, D.A., G. Winters, W.E. Drane, E.L. Cattau, S.J. Chobanian and A. Dubois, 1987. Solid phase gastric emptying in Barrett's esophagus. Dig Dis. Sci., 9: 23-27.
99:   Johnson, D.A., H. Etter and D. Reeves, 1983. Stroke and phenylpropanolamine use. Lancet, 2: 970-970.
100:   Johnson, D.A., J. Crawley, C. Hwang and K. Brown, 2010. Clinical trial of esomprazole for moderate to severe nighttime heartburn and gastro-oesophageal reflux related sleep disturbances- a randomized controlled trial with esomeprazole. Aliment Pharmacol. Ther., 32: 182-190.
CrossRef  |  
101:   Johnson, D.A., J. Hancock and E.L. Cattau Jr., 1986. Pediatric primary sclerosing cholangitis. Dig. Dis. Sci., 31: 773-777.
CrossRef  |  Direct Link  |  
102:   Johnson, D.A., J.E. Richter, P.O. Katz, R. Hinder, R. Shaker, S. Santag and N. Flack, 2000. Yale consensus conference on extraesophageal GERD. J. Clin. Gastroenterol., 30: 2-53.
103:   Johnson, D.A., J.R. Hacker, S.B. Benjamin, S.J. Chobanian, M.M. van Ness and E.L. Jr. Cattau, 1987. Percutaneous endoscopic gastrostomy effects on gastroesophageal reflux and the lower esophageal sphincter. Am. J. Gastroenterol., 82: 622-624.
PubMed  |  
104:   Johnson, D.A., K. Wagner and J. Blanks, 1984. Diagnosis of legionnaire's disease. J. Am. Med. Assoc., 251: 3079-3080.
105:   Johnson, D.A., K.F. Wagner and J. Blanks, 1985. False-positive direct fluorescent antibody testing for Legionella. J. Am. Med. Assoc., 253: 40-41.
CrossRef  |  Direct Link  |  
106:   Johnson, D.A., P. Aulicino and J.G. Newby, 1984. Bacillus cereus-induced myonecrosis. J. Trauma, 24: 267-270.
CrossRef  |  PubMed  |  Direct Link  |  
107:   Johnson, D.A., P.W. Stafford and R.J. Volpe, 1985. Ischemic bowel infection and phenylpropanolamine. J. Med., 142: 399-400.
108:   Johnson, D.A., R. Ganz and J. Aisneberg et al., 2003. Endoscopic, deep mural implantation of ENERYX for the treatment of GERD: 6 month follow-up of a multicenter trial. Am. J. Gastroenterol., 98: 250-258.
109:   Johnson, D.A., R. Ganz, J. Aisenberg, L.B. Cohen and J. Deviere et al., 2000. Endoscopic implantation of Enteryx for GERD treatment: 12 month results of a prospective multicenter trial. Am. J. Gastroenterol., 98: 1921-1930.
PubMed  |  
110:   Johnson, D.A., S.J. Chobanian and E.L. Cattau Jr., 1985. Physiology of hyper-salivation syndrome. J. Am. Med. Assoc., 253: 2831-2832.
111:   Johnson, D.A., W. Orr and B. Taxler, 2005. Sleep dysfunction in gastroesophageal reflux disease- a randomized multicenter controlled trial with esomeprazole. Am. J. Gastroenterol., 100: 1914-1922.
112:   Johnson, D.A., W.E. Drane, J. Curran, S.B. Benjamin, S.J. Chobanian, K. Karvelis and E.L. Jr. Cattau, 1987. Metoclopramide response of esophageal and gastric motor abnormalities in patients with progressive systemic sclerosis. Arch. Intern. Med., 147: 1597-1601.
113:   Johnson, D.A., W.E. Drane, J.C. Curran, A. Khan, C.A. Cianleglio, E.L. Jr. Cattau and S.B. Benjamin, 1989. Gastroesophageal reflux and pulmonary function tests in progressive systemic sclerosis. Arch. Intern. Med., 149: 589-593.
114:   Johnson, D.A., Z. Younes and W.H.Hogan, 2000. Endoscopic assessment of anti-reflux repairs. Gastrointest Endosc, 52: 1-10.
115:   Johnson, D.A., Z. Younes and W.J. Hogan, 2000. Endoscopic assessment of hiatal hernia repair. Gastrointest Endosc, 52: 650-659.
PubMed  |  
116:   Johnson. D.A. and E.L. Jr. Cattau, 1988. Gastrointestinal Drugs in the Critically Ill Patient. In: The Pharmacologic Approach to the Critically Ill Patient, Chernow, B. (Ed.). Williams and Wilkins, Baltimore, MD., pp: 322-346.
117:   Kahrilas, P.J., D.A. Johnson and J.E. Richter, 2000. Esomeprazole: Effects of a new proton pump inhibitor on gastroesophageal reflux disease. Aliment Pharmacol. Ther., 14: 1267-1272.
118:   Karvelis, K.C., W. Drane, D.A. Johnson and E.D. Silverman, 1987. Barrett's esophagus: Decreased clearance shown by radionuclide esophageal scintigraphy. Radiology, 162: 97-99.
PubMed  |  
119:   Kim, H.N., R.D. Vorona, M.P. Winn, M. Doviak, D.A. Johnson and J.C. Ware, 2005. Symptoms of gastro-oesophageal reflux disease and the severity of obstructive sleep apnoea syndrome are not related in sleep disorders center patients. Aliment Pharmacol. Ther., 35: 1127-1133.
PubMed  |  
120:   Lawson, M.J. and D.A. Johnson, 1993. Gastric Ulcer. In: Manual of Clinical Problems in Gastroenterology, Van Ness, N.M. and S.J. Chobanian (Eds.). Little, Brown and Company, Boston, MA., pp: 51-54.
121:   Lawson, M.J. and D.A. Johnson, 1993. Gastritis. In: Manual of Clinical Problems in Gastroenterology, Van Ness, N.M. and S.J. Chobanian (Eds.). Little, Brown and Company, Boston, MA., pp: 48-51.
122:   Levin, T.R., J. Bond, S. Winawer, D. Rex and D. Johnson, 2005. Quality in the technical performance of Flexible sigmoidoscopy: Recommendations of an international multisociety task force. Gut, 54: 807-813.
123:   Rex, D.K., D. Provenzale, D.A. Johnson and D. Lieberman, 2000. Colorectal cancer prevention 2000: Screening recommendations. American college of gastroenterology. Am. J. Gastroenterol., 95: 868-877.
PubMed  |  
124:   Rex, D.K., J.H. Bond, S. Winawer, T.R. Levin and R.W. Burt et al., 2002. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: Recommendations of the U.S. multi-society task force on colorectal cancer. Am. J. Gastroenterol., 97: 1296-1308.
PubMed  |  
125:   Schiller, L. and D.A. Johnson, 2008. FDA and drug recall decisions. Am. J. Gastroenterol., 103: 815-819.
126:   Schwegher, E., L. Cazares, L. Steele, D.A. Johnson and R. Drake, 2005. Seldi TOF-MS profiling for detection of progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology, 41: 634-642.
127:   Sharma, P. and D.A. Johnson, 2008. Multicultural issues in gastroesophageal reflux disease: A systematic review. Am. J. Gastroenterol., 103: 2669-2680.
128:   Toghanian, S., D.A. Johnson and S. Bolge, 2010. The burden of disrupting gastroesophageal reflux disease: A database study in us and european cohorts. Clin. Drug Invest., 30: 167-178.
129:   Vakil, N.B., R. Shaker, D.A. Johnson, T. Kovacs and R.D. Baerg et al., 2001. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: A 6 month randomized double blind controlled trial. Aliment Pharmacol. Ther., 15: 927-935.
PubMed  |  
130:   Vinik, A.I., A. Mehrabyan and D.A. Johnson, 2004. Gastrointestinal Disturbances in Diabetes. In: Therapy for Diabetes Mellitus and Related Disorders, Lebovitz, H.E. (Ed.). American Diabetes Association, USA., pp: 424-39.
131:   Wahlqvist, P., M. Karlsson, D. Johnson, J. Carlsson, S.C. Bolge and M.A. Wallander, 2008. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: Survey of a US cohort. Aliment Pharmacol. Ther., 27: 960-970.
CrossRef  |  
132:   Winters, C. and D.A. Johnson, 1987. Barrett’s esophagus. N. Eng. J. Med. (Lett.), 316: 276-277.
133:   Winters, C., T.J. Spurling, S.J. Chobanian, D.J. Curtis and R.L. Esposito et al., 1987. Barrett's esophagus: A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology, 92: 118-124.
PubMed  |  
134:   Wootton, F.T. and D.A. Johnson, 1994. GI bleeding in geriatric patients. Contemporary Gastroenterol., 18: 11-17.
135:   Younes, Z. and D.A. Johnson, 1999. Congenital esophageal stenosis: Clinical endoscopic features in adults. Dig Dis., 17: 172-177.
PubMed  |  
136:   Younes, Z. and D.A. Johnson, 1999. The spectrum of spontaneous and iatrogenic esophageal injury- perforations, Mallory-Weiss tears and hematomas. J. Clin. Gastroenterol., 29: 306-317.
PubMed  |  
137:   Younes, Z. and D.A. Johnson, 2000. New developments and concepts in antimicrobial therapy for intra abdominal infections. Curr. Gastroenterol. Rep., 2: 277-282.
PubMed  |  
138:   Younes, Z., D.A. Johnson and M.J. Ryan, 2000. GI manifestations of ehrlichiosis. Gastroenterol. Observer, 19: 2-4.
139:   Younes, Z.H., D.A. Johnson and L. Dimick, 1998. Sigmoid anal intussusception presenting as rectal prolapse: Role of endoscopic diagnosis. Gastrointest Endosc, 47: 561-563.
PubMed  |